Join Parexel’s experts as they showcase the latest research and outcomes. Our posters – some developed in collaboration with our clients – highlight important advances that impact innovation, value and healthcare decision-making.
View an overview of Parexel’s posters below. Please connect with our authors to find out more or visit us at booth #904.
ISPOR Europe (Glasgow) 2025: POSTERS
AI and automation in data analysis, clinical development and HTA processes
Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions
MSR37: Find out more
Exploring Artificial Intelligence’s (AI's) Role in Literature Screening: A Comparative Analysis Paving the Way for More Efficient Evidence Synthesis
MSR102: Find out more
A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-enabled Interventions: Uncovering Trends and Potential Implications
SA1: Find out more
Decoding the Future: How Are HTA Agencies Evaluating AI in Healthcare
HTA102: Find out more
Large Language Model (LLM) as Catalyst for Rapid and Efficient Critical Appraisal of Epidemiological Research
EPH156: Find out more
From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding
PT29: Find out more
Evolving trends in individual and/or joint HTA assessments, including Joint Clinical Assessment (JCA)
Advancing Cost-Effectiveness Modeling with R: A Flexible Approach for HTA Submissions
EE43: Find out more
Enhancing Patient Involvement in European Health Technology Assessment (HTA): From Inconsistent National Practices to Systematic Engagement in Joint Clinical Assessments
HTA124: Find out more
NICE decisions in the South-West quadrant
HTA252: Find out more
Landscaping for product/therapy availability, positioning and reimbursement potential
Budget impact of nivolumab plus ipilimumab plus chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer in Switzerland
EE111: Find out more
Costs and Number Needed to Treat (NNT) to Achieve Improvements With C5 Inhibitors in Generalized Myasthenia Gravis From the Japanese Healthcare Perspective: A Network Meta-Analysis
EE287: Find out more
Economic Evaluations Cost and Resource Utilization in Early Triple-Negative and Low Hormone Receptor-Positive Breast Cancer: A Comprehensive Systematic Review
EE395: Find out more
Modelling What Matters: The Real-World Burden of Pregnancy-Related Complications in cTTP
EE591: Find out more
Navigating Reimbursement Challenges for Pharmacological Interventions in Coeliac Disease: Lessons from Analogous Conditions
HTA248: Find out more
Unveiling the Economic Landscape: Burden of HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer
EE745: Find out more
Novel data analytics approaches to improve clinical and medical data interpretation, value demonstration and pricing strategies
Bayesian Parametric Mixture Cure Survival Models With Delayed Treatment Effects and Application to Targeted Therapies in Advanced Ovarian Cancer
MSR45: Find out more
Evaluation of the measurement properties of the German LupusPROTM for Swiss-German SLE patients
MSR99: Find out more
Is less more? Aggregating health states in state transition models
EE562: Find out more